Watch the video and download the slides

Dr Matthew Matasar is a board-certified medical oncologist/hematologist, who received his undergraduate and medical degrees from Harvard University. His internal medicine training was completed at Columbia Presbyterian, where he earned a Master’s in biostatistics, while serving as Chief Resident. His fellowship training was in medical oncology at Memorial Sloan Kettering Cancer Center, where he subsequently joined faculty on the Lymphoma and Adult BMT services. Dr Matasar is also the Director of the Lymphoma Survivorship Clinic, where he focuses on the management of long-term survivors of Hodgkin and non-Hodgkin lymphoma. As the Section Head for Aggressive B-cell Lymphomas, his research is focused on improving outcomes in relapsed but curable patients using novel therapies. He is the Medical Director at MSK Bergen, directing a team of expert oncologists in the delivery of cutting-edge care across cancer service lines to patients at the free-standing outpatient center in Montvale, New Jersey.

Dr Matthew J. Matasar has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Bayer Pharmacyclics, Genentech, GlaxoSmithKline, Immunovaccine Tech, Janssen, Juno Theraputics, Merck, Roche Rocket Medical, Seattle Genetics, Teva and Takeda.

 

 

 

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Accreditation
EACCME
This course has been accredited by EACCME® for 1 ECMEC®.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LYMPHOMA & MYELOMA CONNECT

LYMPHOMA & MYELOMA CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Karyopharm Therapeutics and Menarini Stemline Oncology.

Meet the experts Independent IME approved

Other programmes of interest

video Video
Oncology Hemato-oncology 
Early relapsed/refractory multiple myeloma (RRMM): best practices in management

A 3-part video series on managing early RRMM from leading medical experts

Experts
Dr Elena Zamagni, Dr Fredrik Schjesvold, Dr Joseph Mikhael
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Sep 2024

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology.
eks
Experts Knowledge Share Video
Oncology Hemato-oncology 
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)

Medical experts discuss the latest learnings from clinical practice

Experts
Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter
  • download Downloadable
    Resources
  • clock MIN
  • calendar Jun 2024

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology.
conference-update Conference update

Episode

6

of 6

episode
Oncology Hemato-oncology 
Listen to Expert Insights on Late-Breaking Data from ASCO 2023

Episode 6: Lymphoma Update: SWOG S1826 trial

Experts
Dr Mansoor Raza Mirza, Dr Paolo Tarantino, Prof. Alexey V Danilov, Prof. Mark Socinski, Prof. Evan Yu, Prof. Thomas Powles, Assoc. Prof. Gerald Prager
  • clock 2 MIN
  • calendar Jun 2023

Oncology Hemato-oncology 
Update From ASH 2022

Highlights from the ASH Annual Meeting

Experts
Dr Matthew J. Matasar
  • clock 4 MIN
  • calendar Dec 2022

Educational programme supported by an Independent Educational Grant from COR2ED.
Hemato-oncology 
Update from ASCO 2022 – Myeloma

Dr Hans Lee summarises the highlights from the phase 3 DETERMINATION trial: Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM)

Experts
Asst. Prof. Hans Lee
  • clock 2 MIN
  • calendar May 2022

podcast Podcast

Episode

3

of 3

episode
Hemato-oncology 
Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics

Episode 3: Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics

Experts
Assoc. Prof. María Victoria Mateos, Dr Alexander M Lesokhin
  • download Downloadable
    Resources
  • clock MIN
  • calendar Mar 2022

Educational programme supported by an Independent Educational Grant from Karyopharm